Cinainu 治疗儿童斑秃的疗效与安全性:国际双盲随机安慰剂对照 II/III 期试验
RAAINBOW 研究纳入 107 例 2–17 岁斑秃患儿,按 2:1 随机接受 Cinainu 或安慰剂治疗 24 周,随后 24 周未治疗随访。主要分析纳入 62 例中重度斑秃患者,Cinainu 在第 24 周 SALT 评分相对变化上显著优于安慰剂,且生活质量改善,随访期获益持续,耐受性良好。
要点
- Cinainu 第 24 周 SALT 相对变化优于安慰剂(调整均差 +26.3%,P=0.0488)。
- Cinainu 组应答率 26.2%,安慰剂组 5.0%(P=0.0484)。
- 随访至第 48 周疗效持续,CDLQI 效应量大(d=0.79)。
核心结论
- Cinainu 在中重度斑秃儿童和青少年中显示出疗效、安全性和随访期持续获益。
研究设计与样本
- 国际、双盲、随机、安慰剂对照 II/III 期试验(RAAINBOW),107 例 2–17 岁斑秃患者按 2:1 随机接受 Cinainu 或安慰剂治疗 24 周,随后 24 周未治疗随访。
- 主要分析纳入 62 例符合中重度斑秃预设标准的患者。
主要发现
- 第 24 周 SALT 评分相对基线变化:调整均差 +26.3%(95%CI 0.1–52.5),P=0.0488,Cohen's d=0.52。
- 第 24 周应答率(SALT 改善≥40%):Cinainu 组 26.2% vs 安慰剂组 5.0%,P=0.0484。
- 第 24 周生活质量改善效应量:CDLQI d=0.61,EQ-VAS d=0.69。
- 随访至第 48 周 SALT 相对变化调整均差 +39.4%(95%CI 13.1–65.6),P=0.0033,Cohen's d=0.80;CDLQI 效应量 d=0.79。
- 未报告与 Cinainu 相关的严重不良事件,治疗耐受性良好。
关键数值与推荐
- 主要终点为第 24 周 SALT 评分相对基线的相对变化。
- 应答定义为第 24 周 SALT 评分较基线改善≥40%。
临床怎么用
- Cinainu 可作为中重度斑秃儿童和青少年的一种潜在外用治疗选择,需关注 24 周疗效及随访期持续获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is a debilitating autoimmune-mediated disorder marked by nonscarring hair loss. It significantly impairs patients' quality of life (QoL). Inflammation and immune dysregulation, especially involving chemokines like interleukin-8 and Janus kinase (JAK)-dependent signalling pathways, underlie AA pathogenesis. As oral JAK inhibitors are approved for severe cases only, unmet needs persist, particularly for paediatric patients and those with moderate AA. Cinainu, a topical solution containing four botanical extracts, may address these gaps due to its anti-inflammatory, anti-apoptotic and antioxidant properties. OBJECTIVES: This phase II/III study evaluated the efficacy and safety of Cinainu in children and adolescents with moderate-to-severe AA. METHODS: The RAAINBOW study, an international, double-blind, placebo-controlled trial, involved 107 paediatric patients randomly assigned (2 : 1) to receive Cinainu or placebo for 24 weeks, followed by a 24-week untreated follow-up period. The primary analysis included 62 patients meeting predefined criteria for moderate-to-severe AA. The primary endpoint was the relative change in Severity of Alopecia Tool (SALT) score from baseline to Week 24. Secondary outcomes included responder rate (≥ 40% improvement in SALT score from baseline to Week 24), absolute SALT score changes, and QoL improvements measured by the Children's Dermatology Life Quality Index (CDLQI) and EuroQol Visual Analogue Scale (EQ-VAS). Safety assessments included treatment-emergent adverse events. This trial is registered with EudraCT: 2016-003208-30 and ClinicalTrials.gov: NCT03240627. RESULTS: Cinainu showed significant benefits compared with placebo in relative change in SALT score from baseline to Week 24: adjusted mean difference [95% confidence interval CI)] + 26.3% (0.1-52.5); P = 0.0488, Cohen's d = 0.52. A significantly higher proportion of Cinainu-treated patients met responder criteria at Week 24 (26.2% vs. 5.0%; P = 0.0484). Cinainu also led to significant QoL improvements at Week 24, with effect sizes of d = 0.61 in CDLQI and d = 0.69 in EQ-VAS. Benefits were sustained during the follow-up period: adjusted mean difference (95% CI) + 39.4% (13.1-65.6); P = 0.0033, Cohen's d = 0.80, in relative change in SALT score from baseline to Week 48 and large effect sizes in CDLQI (d = 0.79). No serious adverse events were related to Cinainu, and treatment was well tolerated. CONCLUSIONS: In this study, Cinainu showed efficacy, safety and sustained benefits during follow-up in children and adolescents with moderate-to-severe AA, a population with significant unmet needs. Alopecia areata (AA) is an autoimmune condition. The body’s immune system attacks hair follicles, causing patchy to total scalp or body hair loss. AA affects about 2 in 100 people worldwide and often starts in childhood or adolescence. AA can be very distressing for people, especially younger people. The condition can impact self-esteem and quality of life. Currently, there is no approved treatment for moderate AA in children. No topical treatment (i.e. applied directly to a body location, such as the scalp) is approved for any form of AA in any age group. This study looked at children and adolescents with moderate-to-severe AA in Bulgaria, France, Germany and India. We tested the safety and effectiveness of a new botanical (i.e. from plants) drug-based topical solution called Cinainu. The study included 107 patients with AA aged 2 to 17 years. Participants were randomly assigned to apply either Cinainu or a placebo solution to their scalp twice daily for 24 weeks. After the treatment ended, participants were followed for another 24 weeks to see whether any benefits lasted. Cinainu led to better hair regrowth compared with the placebo. By Week 24, children with AA using Cinainu had 26% more hair regrowth on average than those using the placebo. More than one in four children using Cinainu had noticeable improvement. This was compared with just one in 20 in the placebo group. Cinainu-treated participants also reported greater improvements in appearance and wellbeing compared with those receiving placebo. These benefits persisted even after treatment ended. Cinainu was well tolerated, with only mild and temporary side effects reported. These results suggest that Cinainu could offer a safe and effective new treatment option for children with moderate-to-severe AA. This will help to fill an important gap in current care.
引用
- Blume-Peytavi U, Piraccini BM, Reygagne P, et al. Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial. Br J Dermatol. 2026. PMID: 40668972. doi:10.1093/bjd/ljaf279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。